Final Patient Treated In Neuralstem Phase II ALS Stem Cell Trial

GERMANTOWN, Md., Aug. 4, 2014  -- Neuralstem, Inc. (NYSE MKT: CUR) announced that the final patient was treated in its Phase II trial using NSI-566 spinal cord-derived neural stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). The multicenter Phase II trial treated 15 ambulatory patients in five different dosing cohorts. The first 12 patients received injections in the cervical region of the spinal cord only, where the stem cells could help preserve breathing function, in escalating doses ranging from five injections of 200,000 cells per injection, to 20 injections of 400,000 cells each.

NanoViricides to Restart its Anti-Ebola Virus Drug Development Program

WEST HAVEN, Conn.-- NanoViricides, Inc. (NYSE MKT:NNVC) (the “Company”) reports that it is restarting its drug development program to combat Ebola virus infections.

The recent Ebola outbreak in West Africa has been the deadliest so far, per the World Health Organization (WHO). Ebola virus causes a deadly disease, with 60% to 90% of infected people dying, depending upon the strain of the virus. Fortunately, it is transmitted only through close contact with an infected person’s body fluids, and not through aerosol or the water route, thus limiting its transmission.

Currently, there are no licensed drugs or vaccines for Ebola, although some vaccines as well as some drug candidates have entered clinical trials.

Ligand Reports Second Quarter 2014 Financial Results

Company Raises 2014 Financial Guidance ----- Company Recently Authorized a Share Repurchase Program ---- Conference Call Begins at 9:00 a.m. Eastern Time Today

SAN DIEGO -- Ligand Pharmaceuticals Incorporated (LGND) today reported financial results for the three and six months ended June 30, 2014, and provided an operating forecast and program updates.

Financial highlights for the second quarter of 2014 include (all comparisons are with the second quarter of 2013):

• Total revenues increased 11% to $10.6 million, and royalty revenues increased 7% to $5.2 million
• Non-GAAP net income from continuing operations was $0.24 per diluted share
• Net income was $0.07 per diluted share

Cellular Biomedicine Group Announces Acquisition of Immune Cell Therapy Technology and U.S. Patent

PALO ALTO, Calif., Aug. 4, 2014  -- Cellular Biomedicine Group Inc. (CBMG) (the "Company"), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced reaching an agreement to acquire Agreen Biotech Co. Ltd. China ("AG") and its founder's U.S. patent for a total cash and equity consideration of $3.28 million in cash, the issuance of 753,522 shares of CBMG common stock and the issuance of 75,000 shares of CBMG restricted stock units.

The acquisition will include the Intellectual Properties ("IP"), assets and talents of this cancer-therapy-focused developmental stage company. The IP is comprised of T Cells Receptor ("TCR") clonality analysis technology and T Central Memory Cell ("Tcm") and Dendritic Cell ("DC") preparation methodologies.